

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.*

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.*

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



**Akeso, Inc.**

**康方生物科技（開曼）有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9926)**

**COMPLETION OF PLACING OF NEW SHARES  
UNDER GENERAL MANDATE**

**Sole Overall Coordinator, Sole Global Coordinator and Lead Bookrunner**

**Morgan Stanley**

**Co-Bookrunner**



The Directors are pleased to announce that all conditions of the Placing have been fulfilled and the completion of the Placing took place on March 28, 2024. Pursuant to the terms and conditions of the Placing Agreement, 24,800,000 Placing Shares have been successfully placed by the Placing Agents to not less than six Placees at the Placing Price of HK\$47.65 per Placing Share.

Reference is made to the announcement of Akeso, Inc. (the “**Company**”) dated March 21, 2024 in respect of the proposed placing of new Shares under general mandate (the “**Announcement**”). Unless otherwise stated, the terms used in this announcement shall have the same meaning as defined in the Announcement.

## **COMPLETION OF THE PLACING**

The Board is pleased to announce that all conditions to the Placing Agreement have been fulfilled and completion of the Placing took place on March 28, 2024. An aggregate of 24,800,000 Placing Shares have been placed by the Placing Agents to not less than six Placees at the Placing Price of HK\$47.65 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing approximately 2.86% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately upon completion of the Placing.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are professional, institutional, or other investors who are third parties independent of the Company and its connected persons.

The Company received net proceeds from the Placing, after deducting the placing commission and other related expenses and professional fees, of approximately US\$149.53 million (equivalent to approximately HK\$1,170.18 million). The Company intends to use the net proceeds for the purposes as disclosed in the paragraph headed “Reasons for the Placing and Use of Proceeds” in the Announcement.

By Order of the Board  
**Akeso, Inc.**  
**Dr. XIA Yu**  
*Chairwoman and executive Director*

Hong Kong, March 28, 2024

*As at the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive Directors, Dr. ZHOU Yi and Mr. XIE Ronggang as non-executive Directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.*